United States – The U. S Drug Enforcement Administration has raised the production output of Vyvanse by around 24 percent to help combat the ADHD drug shortage across the country.
FDA Requests Production Increase
The DEA approved the increase in production after the FDA requested it, as revealed in a notice from Bloomberg News. The FDA’s request was made in July, as reported by The Hills.
In order to clear the drug shortage problem that has been a major issue for quite a long time, the DEA has increased the production quota for the ADHD medications that are produced by Takeda Pharmaceutical Company and its rivals.
The shortage was already predicted by Adderall in 2022. The drug was initially prescribed for ADHD and narcolepsy.
Controlled Substance
Lisdexamphetamine is a Schedule II substance controlled by the DEA due to the high dependency likelihood and possibility of misuse.
Production Increases
“These adjustments are needed so that the United States has a steady source of lisdexamfetamine for its inherent and legitimate patient demand both in the domestic and international market,” the DEA explained in the notice as it revealed that the production limit for lisdexamfetamine has increased by 6,236 kilograms, as reported by The Hills.
Of this quantity, 4,678 kg was exported to meet more demand from foreign markets, while 1,558 kg was home consumption.
“Extrapolation utilizing previous years’ reported data suggests the export requirements for lisdexamfetamine active pharmaceutical ingredient and finished dosages likely will continue to increase in 2024 and beyond,” the DEA said. “An increase in domestic manufacturing of the active pharmaceutical ingredient and finished dosages is necessary to supply lisdexamfetamine products to foreign markets.”